C08B37/0063

High molecular weight esthetic compositions
11730691 · 2023-08-22 · ·

Described are high molecular weight glycosaminoglycan (GAG) hydrogel compositions comprising GAGs covalently crosslinked with a carbohydrate crosslinker, and methods of making the high molecular weight GAG hydrogel compositions. Further described are methods of using the high molecular weight glycosaminoglycan (GAG) hydrogel compositions for reparative or plastic surgery, esthetic dermatology, facial contouring, body contouring, and gingival augmentation.

GLYCOPHOSPHOLIPID POLYMERIC NETWORK AND USE THEREOF

A biomedical device having a coating on a surface thereof, where the coating includes a glycophospholipid polymer which is a reaction product of one or more glycosaminoglycans and one or more phospholipids.

Nitric oxide-releasing polyaminoglycosides as biodegradable antibacterial scaffolds and methods pertaining thereto

Provided herein are hyperbranched polyaminoglycosides, where in some embodiments, the hyperbranched polyaminoglycosides are covalently modified to store and release nitric oxide. Some embodiments pertain to methods of making and use of hyperbranched polyaminoglycosides. In some embodiments, the covalently modified hyperbranched polyaminoglycosides may be tailored to release nitric oxide in a controlled manner and are useful for eradication of both gram positive and gram negative bacteria as well as other microbes.

LOW MOLECULAR WEIGHT CHONDROITIN SULFATE, COMPOSITION, PREPARATION METHOD AND USE THEREOF
20230250199 · 2023-08-10 ·

The invention relates to a low molecular weight sulfate chondroitin and a preparation method thereof. A low molecular weight chondroitin sulfate with the average molecular weight of less than 1000 Dalton can be obtained by a production process of chondroitin sulfate lyase degradation, deproteinization, filtration and sterilization and drying using macromolecular sulfate chondroitin as a raw material. The low molecular weight Chondroitin sulfate has a narrow molecular weight distribution range, the ratio of chondroitin sulfate disaccharide is 43˜60% and the ratio of chondroitin sulfate tetrasaccharide is 30˜45%, the sum of chondroitin sulfate disaccharide and chondroitin sulfate tetrasaccharide is more than 87%, the total oligosaccharide content of low molecular weight chondroitin sulfate is more than 97% and the protein content is less than 0.5%; Compared with the general market macromolecule chondroitin sulfate, the product has more remarkable repair effect at the concentration of 50˜100 μg/mL on chondrocytes damaged by 1 mM hydrogen peroxide, with strong repair ability and repair rate of 14%˜23%. The low molecular weight chondroitin sulfate can be used to treat joint injury and is an important raw material for medical products, health care products, cosmetics and food.

MATRICES COMPRISING A MODIFIED POLYSACCHARIDE

The present invention discloses a matrix comprising a modified polysaccharide consisting of repeating disaccharide units whereby in at least 11% of the disaccharide units one primary alcohol group is oxidized into a carboxylic acid group.

Glycosaminoglycan derivative and preparation method therefor and use thereof

Disclosed are a carboxylated glycosaminoglycan derivative, a preparation method therefor, and the use thereof for inhibiting tumor growth and/or metastasis.

PREPARATION AND/OR FORMULATION OF PROTEINS CROSS-LINKED WITH POLYSACCHARIDES
20220008612 · 2022-01-13 ·

Therapeutic compositions and/or formulations are provided, comprising: at least one cross-linked protein matrix, wherein the at least one cross-linked protein matrix comprises at least one protein residue and at least one saccharide-containing residue, and methods of producing the same. The cross-linked protein matrix may be derived from cross-linking a full length or substantially full length protein, such as tropoelastin, elastin, albumin, collagen, collagen monomers, immunoglobulins, insulin, and/or derivatives or combinations thereof, with a saccharide containing cross-linking agent, such as a polysaccharide cross-linking agent derived from, for example, hyaluronic acid or a cellulose derivative. The therapeutic compositions may be administered topically or by injection. The present disclosure also provides methods, systems, and/or kits for the preparation and/or formulation of the compositions disclosed herein.

METHOD FOR DECOLORIZING AND DEPROTEINIZING BROWN ALGAE POLYSACCHARIDES
20220010035 · 2022-01-13 ·

A method for decolorizing and deproteinizing brown algae polysaccharides belongs to the field of deep processing of brown algae. The method combines ultraviolet (UV) with hydrogen peroxide (H.sub.2O.sub.2), including the following steps: extracting dried and pulverized brown algae by hot water to obtain brown algae polysaccharide, dissolving the brown algae polysaccharide in an aqueous solution containing H.sub.2O.sub.2 and irradiating under ultraviolet light, wherein the mass concentration of the brown algae polysaccharide is 2.5-10.0 mg/mL, the concentration of the H.sub.2O.sub.2 is 25-150 mmol/L, and the UV irradiation time is 1.0-2.0 h, so as to deproteinize and decolorize the brown algae. The invention does not use acids, bases and organic solvents, which is green with no pollution, simple in operation, safe, economical and time-saving.

Low contaminant compositions
11173199 · 2021-11-16 · ·

Disclosed are antimicrobial vaccines comprising oligosaccharide β-(1.fwdarw.6)-glucosamine groups.

SULFATED GLYCOSAMINOGLYCAN BIOMATERIALS AS PROTEOGLYCAN MIMICS
20220000905 · 2022-01-06 ·

Polymer conjugates are provided that are capable of mimicking functions of natural proteoglycans found in the extracellular matrix of connective tissues. The polymer conjugates of the invention have utility in treating a subject suffering soft tissue conditions. Also provided are simple and scalable chemical processes for the preparation of the polymer conjugates of the invention.